Samchundang Pharm Receives European Approval for Eylea Biosimilar

Samchundang Pharm announced on August 20 that it had received confirmation from its European regulatory agency that its Eylea biosimilar, 'Vial & PFS', has been approved by the European Medicines Agency (EMA).

A company representative stated, "Receiving approval in Europe, the world's second-largest market after the United States, demonstrates the competitiveness of Samchundang Pharm's Eylea biosimilar." He added, "We registered the product under two different brand names, with plans to market the Eylea biosimilar separately in Eastern and Western Europe." He continued, "We are also proceeding with production without any setbacks to ensure the product can be sold in the European market as soon as the patent expires."

Finally, he said, "Samchundang Pharm will ensure that the Eylea biosimilar is sold without any issues so that our partner can achieve its targeted sales figures." He further noted, "As we have mentioned several times before, 80% of Eylea sales have been through PFS, and following Canada, it is highly likely that Samchundang Pharm will be the first to sell PFS in Europe as well."

This content was produced with the assistance of AI translation services.